Meropenem - Antibiogram Data

Outpatients (All Isolates)
% of Isolates Susceptible

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

4.8% of combined E.coli, K.pneumoniae and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

May produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility.

4.8% of combined E.coli, K.pneumoniae and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive

4.8% of combined E.coli, K.pneumoniae and P.mirabilis isolates were ESBL (extended spectrum beta-lactamase) positive

Note

  • January 1, 2018 - December 31, 2018

  • R: Intrinsically resistant or less than 25% empiric susceptibility